Science
-
Research updates, January 28
More research news
-
Long COVID is a smoldering threat to wildland firefighters
Editor’s note: This story was originally published in October 2022 by High Country News and was supported by The Economic Hardship Reporting Project. Researchers found that particulate matter from wildfires can increase risk of COVID-19 and that wildland firefighters may be at a higher risk of developing Long COVID due to a variety of factors.…
-
Finding an accepted Long COVID biomarker will be complicated. This blood test could give us answers.
Last year, immunologist Johan Van Weyenbergh published a study in The Lancet: Microbe that identified a potential blood-based biomarker for Long COVID with 94% sensitivity. Van Weyenbergh’s team discovered SARS-CoV-2 RNA transcripts in the blood cells of people with Long COVID. They also found a specific type of RNA, called ORF1ab RNA, which suggested there…
-
Research updates, January 21
The U.S. government is funding a $375 million effort for a new COVID-19 prevention drug for immunocompromised people, as part of Project NextGen. The federal health department provided the funds to the drug company Shionogi Inc. for a long-acting pre-exposure prophylactic (PreP) called S-892216 that blocks the main protease of SARS-CoV-2.
-
Immune system damage from COVID-19 is different from HIV/AIDS — but the advocacy has parallels
Lymphopenia is a health condition in which people have low white blood cell count in their blood. Without these cells, the body is unable to defend itself effectively against pathogens. Lymphopenia is one type of way your body can be immunocompromised; it can be caused by many things, including infections, inherited conditions, autoimmune disorders, and…
-
Research updates, January 14
-
Research updates, January 7
*Editor’s note: Julia Moore Vogel, an author of Paxlovid study, is on The Sick Times’ advisory board. Other authors are also affiliated with the Patient-Led Research Collaborative, which shares a funding source (the Balvi and Kanro funds) with The Sick Times. One author (JD Davids) is affiliated with Long COVID Justice, with which we collaborated…
-
Research updates, December 24
A 2020 paper that spread controversial claims about the anti-malarial drug hydroxychloroquine as a treatment for COVID-19 was retracted last week. Published in the International Journal of Antimicrobial Agents, the paper was pulled for ethical concerns and other methodological problems. Earlier in the pandemic, the paper led to shortages of the drug for people with…
-
Research updates, December 17
Editor’s note, December 19, 11am EST: The fourth summary has been updated to correct information about the patients who were autopsied. Related stories
-
NIH announces $147 million in additional Long COVID research funding, new budget details
The U.S. National Institutes of Health (NIH) has announced further funding for its flagship Long COVID research program, called RECOVER, as well as new details about the program’s budget through 2029. RECOVER will receive an additional $147 million, building on $515 million allocated earlier this year and the original $1.15 billion funded by Congress in…
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
-
Trans people with Long COVID navigate a new “dark age” in trans health
-
National COVID-19 trends, October 13
-
Research updates, October 13
-
How I built a COVID-safer school that’s become the heart of a more caring community
-
Biological pathways and mechanistic trials centered at new Long COVID conference in Amsterdam
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance